

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE YEAR ENDED 31 DECEMBER 2022

On 30 January 2023, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2022.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 21.96% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 30 January 2023, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2022, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the year ended 31 December 2022 is estimated to range from approximately RMB760 million to RMB810 million (as compared to the same period last year of net profit of approximately RMB440.44 million), net profit excluding non-recurring gain or loss is estimated to range from approximately RMB686.37 million to RMB736.37 million (as compared to the same period last year of net profit of approximately RMB352.38 million), basic earnings per share is estimated to range from approximately RMB1.18 per share to approximately RMB1.26 per share (as compared to same period last year of profit per share of approximately RMB0.68 per share) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

1. In 2022, Dong-E-E-Jiao deeply implemented the principle of “reshaping values, businesses, organisation and ethos” to ensure its quality, motivate its teams, set examples for the industry, secure the life for the people and forge the soul of the nation. It adhered to the consumer-oriented principle, put more efforts on customer operation and continued to enhance brand awareness and revive the brand, so as to strengthen the position of Dong-E-E-Jiao as the first-tier national brand name for nourishment products. The growth model underpinned by “pharmaceutical + consumer health product” as dual drivers was established, digital marketing was strengthened, and product expansion was achieved with the support of research and development and innovative capabilities. It also focused on the central cities of key provinces and enhanced the efficiency of resource allocation, as a result of which the shelf sales ratio was improved significantly. The organisational structure for marketing was reconstructed to improve organisational effectiveness and stimulate organisational vitality.
2. In the future, Dong-E-E-Jiao will continue to integrate itself into the national big health development strategy, focus on the business model underpinned by “pharmaceutical” and “consumer health products” as dual drivers, optimise the layout of product categories systematically, achieve comprehensive scientific product planning and build a future-oriented, digitalised and flexible operation system based on the development strategy of “consolidating of principal business, making continuous breakthroughs and innovative exploration”, stabilise its leading position in the nourishment sector by innovative development, and strive to become the most trusted leader in Chinese nourishing sector for consumers.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2022 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 31 January 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.